MIMEDX GROUP, INC.MDXG
時価総額
$10.7億
PER
胎盤由来アロガフト製品の有力企業。EPIFIXやAMNIOEFFECT、AXIOFILLなどの組織移植製品を展開。2023年末にEPIEFFECTを発売、2024年にHELIOGEN投入、同年TELA販売権を取得(初期対価500万ドル)。米国を中心に日本へ拡大。
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Cash and cash equivalents | 4 | 7 | 44 | 47 | 28 | 34 | 45 | - | 96 | 87 | 66 | 82 | 104 |
| Accounts receivable, net | 2 | 8 | 16 | 27 | 54 | 67 | - | - | 35 | 40 | 43 | 54 | 56 |
| Inventory | 712,602 | 3 | 4 | 5 | 7 | 18 | 16 | - | 10 | 11 | 13 | 21 | 24 |
| Prepaid expenses | - | - | - | - | - | 6 | 7 | - | 6 | 6 | 9 | 6 | 5 |
| Other current assets | - | - | - | - | - | 1 | 6 | - | 3 | 3 | 3 | 2 | 3 |
| Total current assets | 7 | 18 | 65 | 86 | 96 | 127 | 74 | - | 161 | 149 | 134 | 164 | 192 |
| Property and equipment, net | - | - | - | - | - | - | - | - | - | 9 | 8 | 7 | 6 |
| Right of use assets | - | - | - | - | - | - | - | - | 4 | 5 | 3 | 2 | 6 |
| Deferred tax assets | - | - | - | - | - | - | - | - | - | - | - | 41 | 28 |
| Goodwill | 4 | 4 | 4 | 4 | 4 | 20 | 20 | - | 20 | 20 | 20 | 19 | 19 |
| Intangible assets, net | 15 | 12 | 11 | 11 | 11 | 23 | 10 | - | 6 | 5 | 6 | 5 | 12 |
| Other assets | 214,342 | 70,000 | - | - | - | - | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total assets | 27 | 35 | 85 | 109 | 136 | 193 | 123 | - | 202 | 188 | 171 | 239 | 264 |
| Current portion of long term debt | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
| Accounts payable | - | - | - | - | - | - | - | - | 9 | 7 | 9 | 9 | 7 |
| Accrued compensation | - | - | 6 | 12 | 15 | 12 | 23 | - | 18 | 24 | 22 | 22 | 24 |
| Accrued expenses | - | 4 | 1 | 3 | 5 | 11 | 32 | - | 30 | 10 | 11 | 9 | 9 |
| Current portion of Profit Share Payments | - | - | - | - | - | 9 | - | - | - | - | - | - | 1 |
| Current liabilities of discontinued operations | - | - | - | - | - | - | - | - | - | - | - | 1 | - |
| Other current liabilities | - | 75,154 | 122,551 | 1 | 0 | 1 | 2 | - | 1 | 2 | 2 | 4 | 3 |
| Total current liabilities | 8 | 5 | 10 | 18 | 27 | 51 | 72 | - | 59 | 42 | 44 | 46 | 46 |
| Long term debt, net | - | - | - | - | - | - | - | - | 48 | 48 | 49 | 48 | 18 |
| Other liabilities | 312,493 | 299,762 | 2 | 2 | 1 | 1 | 2 | - | 4 | 5 | 5 | 2 | 7 |
| Total liabilities | 15 | 15 | 11 | 20 | 28 | 60 | 73 | - | 111 | 95 | 97 | 96 | 71 |
| Common Stock, Value, Issued | 74,307 | 88,423 | 104,426 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Additional paid-in capital | 74 | 90 | 147 | 162 | 163 | 161 | 165 | - | 159 | 166 | 174 | 276 | 284 |
| Accumulated deficit | -62,021,346 | -69,683,722 | -73,795,575 | -68 | -38 | -26 | -77 | - | -151 | -162 | -192 | -134 | -91 |
| Total stockholders’ equity | 12 | 20 | 74 | 89 | 108 | 133 | 50 | - | -0 | 0 | -18 | 143 | 193 |
| Total liabilities and stockholders’ equity | 27 | 35 | 85 | 109 | 136 | 193 | 123 | - | 202 | 188 | 171 | 239 | 264 |